114 related articles for article (PubMed ID: 30175278)
1. Pharmacogenetic Labeling of FDA-Approved Drugs: A Regulatory Retrospective.
Drozda K; Pacanowski MA; Grimstein C; Zineh I
JACC Basic Transl Sci; 2018 Aug; 3(4):545-549. PubMed ID: 30175278
[TBL] [Abstract][Full Text] [Related]
2. [Warfarin resistance and related pharmacogenetic information].
Takahashi H
Brain Nerve; 2008 Nov; 60(11):1365-71. PubMed ID: 19069171
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenomics and warfarin therapy.
Ndegwa S
Issues Emerg Health Technol; 2007 Oct; (104):1-8. PubMed ID: 17912794
[TBL] [Abstract][Full Text] [Related]
4. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.
Shaw K; Amstutz U; Hildebrand C; Rassekh SR; Hosking M; Neville K; Leeder JS; Hayden MR; Ross CJ; Carleton BC
Pediatr Blood Cancer; 2014 Jun; 61(6):1055-62. PubMed ID: 24474498
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation.
Eckman MH; Rosand J; Greenberg SM; Gage BF
Ann Intern Med; 2009 Jan; 150(2):73-83. PubMed ID: 19153410
[TBL] [Abstract][Full Text] [Related]
6. A regulatory science perspective on warfarin therapy: a pharmacogenetic opportunity.
Kim MJ; Huang SM; Meyer UA; Rahman A; Lesko LJ
J Clin Pharmacol; 2009 Feb; 49(2):138-46. PubMed ID: 19179293
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenomics of warfarin: uncovering a piece of the warfarin mystery.
Gulseth MP; Grice GR; Dager WE
Am J Health Syst Pharm; 2009 Jan; 66(2):123-33. PubMed ID: 19139476
[TBL] [Abstract][Full Text] [Related]
8. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives.
Yin T; Miyata T
Thromb Res; 2007; 120(1):1-10. PubMed ID: 17161452
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenomics in the assessment of therapeutic risks versus benefits: inside the United States Food and Drug Administration.
Zineh I; Pacanowski MA
Pharmacotherapy; 2011 Aug; 31(8):729-35. PubMed ID: 21923598
[TBL] [Abstract][Full Text] [Related]
10. Preliminary outcomes of preemptive warfarin pharmacogenetic testing at a large rural healthcare center.
Leary E; Brilliant M; Peissig P; Griesbach S
Am J Health Syst Pharm; 2019 Feb; 76(6):387-397. PubMed ID: 31415684
[TBL] [Abstract][Full Text] [Related]
11. Is personalized medicine a dream or a reality?
Morse BL; Kim RB
Crit Rev Clin Lab Sci; 2015 Feb; 52(1):1-11. PubMed ID: 25181036
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenomics of cardiovascular drugs and adverse effects in pediatrics.
Visscher H; Amstutz U; Sistonen J; Ross CJ; Hayden MR; Carleton BC
J Cardiovasc Pharmacol; 2011 Sep; 58(3):228-39. PubMed ID: 21386709
[TBL] [Abstract][Full Text] [Related]
13. Warfarin pharmacogenomics: recommendations with available patented clinical technologies.
Borkowski AA; Kardani A; Mastorides SM; Thomas LB
Recent Pat Biotechnol; 2014; 8(2):110-5. PubMed ID: 25185986
[TBL] [Abstract][Full Text] [Related]
14. The Influence of CYP2C9 and VKORC1 Gene Polymorphisms on the Response to Warfarin in Egyptians.
Bedewy AML; Sheweita SA; Mostafa MH; Kandil LS
Indian J Hematol Blood Transfus; 2018 Apr; 34(2):328-336. PubMed ID: 29622878
[TBL] [Abstract][Full Text] [Related]
15. Failure of pharmacogenetic-based dosing algorithms to identify older patients requiring low daily doses of warfarin.
Schwartz JB; Kane L; Moore K; Wu AH
J Am Med Dir Assoc; 2011 Nov; 12(9):633-8. PubMed ID: 21450231
[TBL] [Abstract][Full Text] [Related]
16. Projected Prevalence of Actionable Pharmacogenetic Variants and Level A Drugs Prescribed Among US Veterans Health Administration Pharmacy Users.
Chanfreau-Coffinier C; Hull LE; Lynch JA; DuVall SL; Damrauer SM; Cunningham FE; Voight BF; Matheny ME; Oslin DW; Icardi MS; Tuteja S
JAMA Netw Open; 2019 Jun; 2(6):e195345. PubMed ID: 31173123
[TBL] [Abstract][Full Text] [Related]
17. Extremely low warfarin dose in patients with genotypes of CYP2C9*3/*3 and VKORC1-1639A/A.
Gao L; He L; Luo J; Xu B; Yang J; Zhang YX; Yang T; Li K; Tian JW; Wang HJ; Zhao YS; Lu CY; Zhang WZ; Yin T
Chin Med J (Engl); 2011 Sep; 124(17):2767-70. PubMed ID: 22040439
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetic impact of VKORC1 and CYP2C9 allelic variants on warfarin dose requirements in a hispanic population isolate.
Palacio L; Falla D; Tobon I; Mejia F; Lewis JE; Martinez AF; Arcos-Burgos M; Camargo M
Clin Appl Thromb Hemost; 2010 Feb; 16(1):83-90. PubMed ID: 19567378
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
